For research use only. Not for therapeutic Use.
Gefitinib(cas 184475-35-2) is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. It is marketed by AstraZeneca and Teva.
| Catalog Number | A000322 |
| CAS Number | 184475-35-2 |
| Synonyms | ZD1839 |
| Molecular Formula | C₂₂H₂₄ClFN₄O₃ |
| Purity | ≥95% |
| Target | EGFR |
| Solubility | >22.3mg/mL in DMSO |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) |
| InChIKey | XGALLCVXEZPNRQ-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 |
| Reference | 1:Rationale design, synthesis, cytotoxicity evaluation, and molecular docking studies of 1,3,4-oxadiazole analogues. Ahsan MJ, Choupra A, Sharma RK, Jadav SS, Hassan MZ, Bakht MA, Padmaja P, Al-Tamimi ABS, Geesi MH.Anticancer Agents Med Chem. 2017 Apr 19. doi: 10.2174/1871520617666170419124702. [Epub ahead of print] PMID: 28425854 |
